ASND Stock Analysis: Ascendis Pharma AS | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 15.572m USD | 12M Return: 20.1% | DK0060615755 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 188M
Qual. Beats: 1
Rev. Trend: 96.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company (NASDAQ: ASND) that develops TransCon-based therapies targeting unmet medical needs, with operations in Europe, the United States, and other international markets. The company is headquartered in Hellerup, Denmark, and was incorporated in 2006.
Ascendis markets two commercial products: SKYTROFA, a treatment for pediatric growth hormone deficiency, and YORVIPATH, a once-daily subcutaneous injection for adults with chronic hypoparathyroidism. The company is also advancing three independent endocrinology rare disease candidates in clinical development, along with oncology therapeutic candidates in its pipeline.
As a biotechnology firm classified within the Health Care sector, Ascendis operates a research-driven business model in which near-term revenue depends on the commercial uptake of approved products, while long-term growth is tied to the progression of its clinical pipeline and regulatory approvals. Its focus on rare endocrine diseases positions the company to pursue orphan drug pathways, which in major markets typically confer extended exclusivity periods for approved indications.
- SKYTROFA revenue grows on pediatric growth hormone market share gains
- YORVIPATH launch drives adult hypoparathyroidism segment revenue ramp
- TransCon pipeline catalysts in rare disease and oncology ahead
| Net Income: 755.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 30.45 > 1.0 |
| NWC/Revenue: 87.74% < 20% (prev 3.66%; Δ 84.08% < -1%) |
| CFO/TA 0.15 > 3% & CFO 351.3m > Net Income 755.8m |
| Net Debt (-263.2m) to EBITDA (78.1m): -3.37 < 3 |
| Current Ratio: 2.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.3m) vs 12m ago 6.90% < -2% |
| Gross Margin: 90.19% > 18% (prev 84.88%; Δ 5.30% > 0.5%) |
| Asset Turnover: 62.52% > 50% (prev 45.11%; Δ 17.41% > 0%) |
| Interest Coverage Ratio: 0.37 > 6 (EBIT TTM 60.4m / Interest Expense TTM 163.9m) |
| A: 0.40 (Total Current Assets 1.39b - Total Current Liabilities 464.7m) / Total Assets 2.29b |
| B: -0.82 (Retained Earnings -1.88b / Total Assets 2.29b) |
| C: 0.04 (EBIT TTM 60.4m / Avg Total Assets 1.69b) |
| D: 1.69 (Book Value of Equity 1.44b / Total Liabilities 849.2m) |
| Altman-Z'' = 1.99 = BBB |
| DSRI: 0.94 (Receivables 224.0m/110.5m, Revenue 1.05b/490.7m) |
| GMI: 0.94 (GM 84.88% / 90.19%) |
| AQI: 8.73 (AQ_t 0.33 / AQ_t-1 0.04) |
| SGI: 2.15 (Revenue 1.05b / 490.7m) |
| TATA: 0.18 (NI 755.8m - CFO 351.3m) / TA 2.29b) |
| Beneish M = 2.30 (Cap -4..+1) = D |
As of September 29, 2026, the stock is trading at USD 230.05 with a total of 747,504 shares traded. Over the past week, the price has changed by -3.17%, over one month by -7.20%, over three months by -12.76% and over the past year by +20.07%.
Current recommended Stop Loss: 208.90 (which is 9.2% or 2.2 ATR below the current price).
Ascendis Pharma AS has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy ASND.
- StrongBuy: 12
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 311.5 | 35.4% |
Market Cap EUR = 13.7b (15.6b USD * 0.87949997186661 USD.EUR)
P/E Trailing = 18.4505
P/E Forward = 21.0084
P/S = 14.8729
P/B = 9.4517
Revenue TTM = 1.05b EUR
EBIT TTM = 60.4m EUR
EBITDA TTM = 78.1m EUR
Long Term Debt = 384.6m EUR (from longTermDebt, last quarter)
Short Term Debt = 65.4m EUR (from shortTermDebt, last quarter)
Debt = 548.7m EUR (from shortLongTermDebtTotal, last quarter) + Leases 98.8m
Net Debt = -263.2m EUR (calculated: Debt 548.7m - CCE 811.9m)
Enterprise Value = 13.4b EUR (13.7b + Debt 548.7m - CCE 811.9m)
Interest Coverage Ratio = 0.37 (Ebit TTM 60.4m / Interest Expense TTM 163.9m)
EV/FCF = 39.87x (Enterprise Value 13.4b / FCF TTM 336.9m)
FCF Yield = 2.51% (FCF TTM 336.9m / Enterprise Value 13.4b)
FCF Margin = 31.95% (FCF TTM 336.9m / Revenue TTM 1.05b)
Net Margin = 71.69% (Net Income TTM 755.8m / Revenue TTM 1.05b)
Gross Margin = 90.19% ((Revenue TTM 1.05b - Cost of Revenue TTM 103.5m) / Revenue TTM)
Gross Margin QoQ = 90.64% (prev 91.37%)
Tobins Q-Ratio = 5.88 (Enterprise Value 13.4b / Total Assets 2.29b)
Interest Expense / Debt = 29.87% (Interest Expense 163.9m / Debt 548.7m)
Taxrate = 10.05% (23.5m / 233.9m)
NOPAT = 54.3m (EBIT 60.4m * (1 - 10.05%))
Current Ratio = 2.99 (Total Current Assets 1.39b / Total Current Liabilities 464.7m)
Debt / Equity = 0.38 (Debt 548.7m / totalStockholderEquity, last quarter 1.44b)
Debt / EBITDA = -3.37 (Net Debt -263.2m / EBITDA 78.1m)
Debt / FCF = -0.78 (Net Debt -263.2m / FCF TTM 336.9m)
Total Stockholder Equity = 396.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 44.82% (Net Income 755.8m / Total Assets 2.29b)
RoE = 190.4% (Net Income TTM 755.8m / Total Stockholder Equity 396.9m)
RoCE = 7.73% (EBIT 60.4m / Capital Employed (Equity 396.9m + L.T.Debt 384.6m))
RoIC = 2.96% (NOPAT 54.3m / Invested Capital 1.83b)
WACC = 7.75% (E(13.7b)/V(14.2b) * Re(6.98%) + D(548.7m)/V(14.2b) * Rd(29.87%) * (1-Tc(0.10)))
Discount Rate = 6.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.50 | Cagr: 8.48%
[DCF] Terminal Value 75.44% ; FCFF base≈336.9m ; Y1≈338.3m ; Y5≈358.3m
[DCF] Fair Price = 88.73 (EV 5.57b - Net Debt -263.2m = Equity 5.84b / Shares 65.8m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 96.43 | Revenue CAGR: 80.36% | SUE: 0.51 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.94 | Chg30d=-1.40% | Revisions=-40% | Analysts=3
EPS current Year (2026-12-31): EPS=12.79 | Chg30d=+12.83% | Revisions=-17% | GrowthEPS=+217.5% | GrowthRev=+90.0%
EPS next Year (2027-12-31): EPS=9.62 | Chg30d=+17.86% | Revisions=-17% | GrowthEPS=-24.8% | GrowthRev=+46.4%
[Analyst] Revisions Ratio: -36% (up=2, down=6)